{"id":11016,"date":"2023-10-15T15:38:00","date_gmt":"2023-10-15T13:38:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=11016"},"modified":"2025-08-07T15:50:10","modified_gmt":"2025-08-07T13:50:10","slug":"pp0916-combination-of-granulocyte-monocyte-apheresis-and-tofacitinib-multicentre-and-retrospective-study","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/pp0916-combination-of-granulocyte-monocyte-apheresis-and-tofacitinib-multicentre-and-retrospective-study\/","title":{"rendered":"PP0916 COMBINATION OF GRANULOCYTE\u2013MONOCYTE APHERESIS AND TOFACITINIB: MULTICENTRE AND RETROSPECTIVE STUDY"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>I. Rodr\u00edguez-Lago1, F. Ca\u00f1ete2, E. Guerra3, C. Herrera de Guise4, E. Iglesias-Flores5, E. Leo-Carnerero6, Y. Zabana7, M. Barreiro de Acosta8, D. Ginard Vicens9, J.L. Cabriada Nu\u00f1o1<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>UEG journal 2023 SUPPLEMENT ABSTRACT UEG Week 2023 Poster Presentations  15 October 2023 page 1067<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>I<strong>ntroduction:<\/strong> Granulocyte\u2013monocyte apheresis (GMA) selectively re\u0002moves activated leukocytes and immune mediators, and it has shown to be safe and effective in treating ulcerative colitis (UC). Previous reports<br>have also described its combination with biologics.<br><strong>Aims &amp; Methods: <\/strong>The aim of our study was to evaluate the efficacy and safety of combining GMA after primary non-response (PNR) or loss of re\u0002sponse (LOR) to tofacitinib (TOFA) in patients with UC. A retrospective, multicentre study was performed in 7 IBD Units, including all patients with refractory UC who received combined plus GMA and TOFA. The number of GMA sessions, its frequency, filtered blood volume and length of each<br>session were compiled, along with the clinical data. Efficacy was assessed 1 and 6 months after finishing GMA by partial Mayo score, CRP and faecal calprotectin. Data regarding TOFA intensification, need for new immuno\u0002modulators\/biologics and colectomy were also compiled. Descriptive sta\u0002tistics and non-parametric tests were used in the statistical analysis.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><strong>Results:<\/strong> Twelve patients with UC were included (median 46 years [IQR, 37-58]; 67% female; 67% E3; 75% non-smokers). Patients were receiving TOFA10 mg bid (75%), 5 mg bid (16%), or 15 mg bid (8%), with 33% receiving<br>steroids at baseline. All patients had prior exposure to anti-TNF agents, 42% to vedolizumab and 8% ustekinumab. Median baseline Mayo score was 7 (IQR, 5-7), median CRP of 11 mg\/L (IQR, 5-32) and faecal calprotectin 800 mg\/kg (IQ, 715-2,094). GMA was started mostly after PNR (73%), and the median number of GMA sessions was 11 (IQR, 3-20) and 50% received maintenance GMA. Partial Mayo score significantly decreased 1 month after the last GMA session (p=0.027). Four patients (36%) were switched to a new therapy and no patient required colectomy during follow-up. All patients under steroids at baseline were able to stop them. No patient re\u0002ported adverse events related to the combination therapy.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><strong>Conclusion:<\/strong> Combination of GMA with TOFA can be an effective and safe therapy in selected cases of UC after PNR or LOR to this drug.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>I. Rodr\u00edguez-Lago1, F. Ca\u00f1ete2, E. Guerra3, C. Herrera de Guise4, E. Iglesias-Flores5, E. Leo-Carnerero6, Y. Zabana7, M. Barreiro de Acosta8, D. Ginard Vicens9, J.L. Cabriada Nu\u00f1o1 UEG journal 2023 SUPPLEMENT ABSTRACT UEG Week 2023 Poster Presentations 15 October 2023 page 1067 Introduction: Granulocyte\u2013monocyte apheresis (GMA) selectively re\u0002moves activated leukocytes and immune mediators, and it has [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[851,303,654,424,435,100,852,789,461,48,309,271,450,306],"class_list":["post-11016","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-biologic-exposed","scientific_tags-combination","scientific_tags-fecal-calprotectin","scientific_tags-gma","scientific_tags-lor","scientific_tags-multicenter","scientific_tags-pcr","scientific_tags-pnr","scientific_tags-refractory","scientific_tags-retrospective","scientific_tags-steroid-free","scientific_tags-study","scientific_tags-tofacitinib","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":"<a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ueg2.12461\">UEG Week 2023 Poster Presentations - 2023 - United European Gastroenterology Journal - Wiley Online Library<\/a>"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>PP0916 COMBINATION OF GRANULOCYTE\u2013MONOCYTE APHERESIS AND TOFACITINIB: MULTICENTRE AND RETROSPECTIVE STUDY - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0916-combination-of-granulocyte-monocyte-apheresis-and-tofacitinib-multicentre-and-retrospective-study\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PP0916 COMBINATION OF GRANULOCYTE\u2013MONOCYTE APHERESIS AND TOFACITINIB: MULTICENTRE AND RETROSPECTIVE STUDY - Adacyte\" \/>\n<meta property=\"og:description\" content=\"I. Rodr\u00edguez-Lago1, F. Ca\u00f1ete2, E. Guerra3, C. Herrera de Guise4, E. Iglesias-Flores5, E. Leo-Carnerero6, Y. Zabana7, M. Barreiro de Acosta8, D. Ginard Vicens9, J.L. Cabriada Nu\u00f1o1 UEG journal 2023 SUPPLEMENT ABSTRACT UEG Week 2023 Poster Presentations 15 October 2023 page 1067 Introduction: Granulocyte\u2013monocyte apheresis (GMA) selectively re\u0002moves activated leukocytes and immune mediators, and it has [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0916-combination-of-granulocyte-monocyte-apheresis-and-tofacitinib-multicentre-and-retrospective-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-07T13:50:10+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0916-combination-of-granulocyte-monocyte-apheresis-and-tofacitinib-multicentre-and-retrospective-study\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0916-combination-of-granulocyte-monocyte-apheresis-and-tofacitinib-multicentre-and-retrospective-study\/\",\"name\":\"PP0916 COMBINATION OF GRANULOCYTE\u2013MONOCYTE APHERESIS AND TOFACITINIB: MULTICENTRE AND RETROSPECTIVE STUDY - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2023-10-15T13:38:00+00:00\",\"dateModified\":\"2025-08-07T13:50:10+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0916-combination-of-granulocyte-monocyte-apheresis-and-tofacitinib-multicentre-and-retrospective-study\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PP0916 COMBINATION OF GRANULOCYTE\u2013MONOCYTE APHERESIS AND TOFACITINIB: MULTICENTRE AND RETROSPECTIVE STUDY - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0916-combination-of-granulocyte-monocyte-apheresis-and-tofacitinib-multicentre-and-retrospective-study\/","og_locale":"fr_FR","og_type":"article","og_title":"PP0916 COMBINATION OF GRANULOCYTE\u2013MONOCYTE APHERESIS AND TOFACITINIB: MULTICENTRE AND RETROSPECTIVE STUDY - Adacyte","og_description":"I. Rodr\u00edguez-Lago1, F. Ca\u00f1ete2, E. Guerra3, C. Herrera de Guise4, E. Iglesias-Flores5, E. Leo-Carnerero6, Y. Zabana7, M. Barreiro de Acosta8, D. Ginard Vicens9, J.L. Cabriada Nu\u00f1o1 UEG journal 2023 SUPPLEMENT ABSTRACT UEG Week 2023 Poster Presentations 15 October 2023 page 1067 Introduction: Granulocyte\u2013monocyte apheresis (GMA) selectively re\u0002moves activated leukocytes and immune mediators, and it has [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0916-combination-of-granulocyte-monocyte-apheresis-and-tofacitinib-multicentre-and-retrospective-study\/","og_site_name":"Adacyte","article_modified_time":"2025-08-07T13:50:10+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0916-combination-of-granulocyte-monocyte-apheresis-and-tofacitinib-multicentre-and-retrospective-study\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0916-combination-of-granulocyte-monocyte-apheresis-and-tofacitinib-multicentre-and-retrospective-study\/","name":"PP0916 COMBINATION OF GRANULOCYTE\u2013MONOCYTE APHERESIS AND TOFACITINIB: MULTICENTRE AND RETROSPECTIVE STUDY - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2023-10-15T13:38:00+00:00","dateModified":"2025-08-07T13:50:10+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0916-combination-of-granulocyte-monocyte-apheresis-and-tofacitinib-multicentre-and-retrospective-study\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/11016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=11016"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=11016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}